VAMP2 and epilepsy: We then analyzed the genetic data from the SYNaPS Study Group collection of exomes and genomes from over 4,000 individuals affected with early-onset neurological disorders (including ∼250 children with undiagnosed neurodevelopmental impairment and epilepsy) for variants in VAMP2 and identified a child (individual 4), carrying a de novo single amino acid deletion at position 43 [NM_014232: c.128_130delTGG (p.Val43del)] (Figures 2A and 2B).